Quantcast

Mirati and BMS to combine sitravatinib and nivolumab for certain non-small cell lung cancer patients in Mirati’s expected Phase 3 trial

Mirati Therapeutics and Bristol-Myers Squibb will work together on evaluating the combination of sitravatinib and nivolumab (OPDIVO), in Mirati’s planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.

Read more

Transgene testing Opdivo with Pexa-Vec to treat HCC – first patient treated

Transgene has treated the first patient in a Phase 1/2 clinical trial for the combination of Pexa-Vec with Opdivo as a first-line treatment of advanced hepatocellular carcinoma (HCC). The trial will assess the safety and tolerability as well as the anti-tumor activity and efficacy of this immunotherapy combination regimen in up to 36 patients (NCT03071094).  This tumour accounts for approximately 75% of liver cancers. 

Read more

BMS and Novartis join forces to fight cancer

Bristol-Myers Squibb and Novartis have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist (trametinib), as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).

Read more

Bristol-Myers and Transgene testing combination of their cancer drugs

Bristol-Myers Squibb and Transgene have entered a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1.

Read more